Nikon will acquire the Optos Group for £259.3 million ($400 million) as part of its long-term plan to expand into the medical sector. Last June, the long-suffering camera giant restructured and unveiled a plan to establish itself again as a growth company--part of that is to leverage its optical technologies to expand into the medical industry.
Neuromodulation company Cyberonics and cardiovascular device player Sorin in an all-stock deal that now values the combination at $3 billion.
So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker Pharmacyclics could be the next company to keep it going.
Boston Scientific sat out most rounds of med tech M&A the past few years, but the device giant might be charting a different course in 2015. The company is reportedly close to buying Endo International's AMS medical device unit in a deal estimated at $2 billion.
Valeant may have inked a pact to buy Salix Pharmaceuticals for more than $10 billion. But that doesn't necessarily mean rival bids aren't on the way.
Outsourced product design specialist TE Connectivity will increase its focus on medical devices with its $190 million purchase of catheter player AdvancedCath.
Everybody sees something different when they look at Eli Lilly, which has recently dropped out of the top 10 pharma group. A number of analysts, some with good reason to shine up to CEO John Lechleiter, see a company that has hit bottom and is on the comeback trail, with new drug approvals to help bolster Lechleiter's bullish forecasts.
2014 is bound to go down as the year of med tech merger mania. FierceMedicalDevices compiles the year's 10 biggest medical device and diagnostic mergers.
Takeda's CEO-in-waiting, Christophe Weber, has included emerging markets, along with oncology and gastrointestinal medicines, as one of three areas of focus. He recently said he is ready to do some deals to capitalize on those areas, and now he has executed one that straddles two of those favorites.
Fresh from completing a $5 billion deal for NPS Pharma, Shire stopped to bag a small San Diego biotech, picking up Meritage Pharma and a Phase III-ready rare disease drug for $70 million upfront and a slate of unspecified milestones.